Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Schering’s Rocky Succession: Former Mining Exec To Head CEO Search

This article was originally published in The Tan Sheet

  • The Tan Sheet

Executive Summary

Schering-Plough interim Chairman Richard Osborne is likely to be wary of mergers as a turnaround strategy for the company

You may also be interested in...



Schering Turnaround Needs 5 Years, CEO Hassan Says; First Step: Buy Time

Schering-Plough CEO Fred Hassan's turnaround plan for the company relies on a careful balance of near-term markers coupled with a message of patience to buy time to execute a five- to seven-year plan

Schering Turnaround Needs 5 Years, CEO Hassan Says; First Step: Buy Time

Schering-Plough CEO Fred Hassan's turnaround plan for the company relies on a careful balance of near-term markers coupled with a message of patience to buy time to execute a five- to seven-year plan

Schering Turnaround Needs 5 Years, CEO Hassan Says; First Step: Buy Time

Schering-Plough CEO Fred Hassan's turnaround plan for the company relies on a careful balance of near-term markers coupled with a message of patience to buy time to execute a five- to seven-year plan

Table

View full table

Related Content

HBW Insight
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope

US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma

US FDA Versus Its Own Precedents

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

See All
UsernamePublicRestriction

Register

PS094803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By